Ludwig Institute for Cancer Research Limited

Other

Oxford University Innovation Limited

Cornell Research Foundation Inc.

Vrije Universiteit Brussel

Johannes Gutenberg-Universität Mainz

Leiden University

University of Leiden

Ludwig Institute of Cancer Research

Pierre Van Der Bruggen

Thierry R Boon-Falleur

Pierre G Coulie

Catia Traversari

Benoit Van Den Eynde

Christophe Lurquin

Pascal Chaux

Etienne De Plaen

Vincent Stroobant

Thierry Boon

Etienne DePlaen

Jean-Christophe Renauld

Beatrice Gaugler

Claude Wildmann

Aline Van Pel

Patrick Chomez

Kris Thielemans

Nathalie Demotte

Alan Townsend

Judy Bastin

Yi Zhang

Jean Herman

Bernard Lethe

Guy R Cornelis

Rosalie Luiten

Erwin Schultz

Marie-Therese Duffour

Katharina Fleischauer

W M Kast

Cornelis J Melief

Jurgen Kurthals

Susanna Mandruzzato

Thomas Gajewski

Francis Brasseur

Charles DeSmet

Olivier DeBacker

Béatrice Guagler

Christophe Lurguin

Immanuel Luescher

Pascale Boel

M W Visseren

Pascale Bo{haeck Over (e)}l

Catie Traversari

Guy Warnier

Lloyd J Old

Janine M Bilsborough

Yao-tseng Chen

Elisabeth Stockert

Jacques Van Snick

Wolfgang J Rettig

Pilar Garin-Chesa

Pedro Romero

Martina Fatho

Volker Lennerz

Vincenzo Russo

Yachi Chen

Bernard Lethé

Jean-Pierre Szikora

Patrick Weynants

Marie Marchand

Francis Basseur

Sjoerd Van Der Burg

Cornelius J Melief

Cornelis J M Melief

P Weynants

M J Visseren

M Marchand

Christoph Lurquin

Emmanuelle Wesarg

Thomas Wölfel

Serena Debo

Thierry Boon Falleur

Karine Breckpot

Christophe Panichelli

Marjan J W Visseren

Martin W Kast

Pascale Bo&euml;l

Thiery Boon-Falleur

Marjan J Visseren

Catherine Wölfel

Marie-Thérèse Duffour

Chris Schmidt

Daniela Eberts

The invention relates to methods and compositions which modulate T lymphocyte activity. It has been found that two, T lymphocyte receptors, especially TCR and CD8, are present at a distance from each other on T lymphocyte surfaces. Via use of modulators which change the distance between these receptors, the activity of the T lymphocyte is modulated.

Method for modulating activity of T lymphocytes

The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs. The present invention furthermore relates to a method for producing an individualized tumour vaccine or individualized tumour therapeutic, as well as corresponding methods for treating a tumourous disease using the individualised tumour vaccine or individualised tumour therapeutic.

Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients

The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.

Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3

Peptides which consist of amino acid sequences found in MAGEA3 bind to HLA-Cw*07 molecules to form T cell epitopes. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.

Isolated peptide which binds to HLA-Cw*07 and uses thereof

The invention describes HLA class II binding peptides encoded by the MAGE tumor associated genes, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of MAGE genes.

MAGE peptides presented by HLA class II molecules

The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.

MAGE-A3 peptides presented by HLA class II molecules

The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant, recombinant, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.

Tumor antigens and CTL clones isolated by a novel procedure

Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor

The invention provides antigenic peptides derived from MAGE polypeptides and presented by HLA-B37 molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.

MAGE-A4 antigenic peptides and uses thereof

The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.

MAGE-3 peptides presented by HLA class II molecules

The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-4 and 41. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Use of these materials in therapeutic and diagnostic contexts are also a part of the invention.

Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereof

The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0&#x2013;10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.

MAGE-A1 peptides presented by HLA class II molecules

A peptide, previously identified as a binding partner of HLA-B44, has now been found to bind to HLA-B18 forming a T cell epitope. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.

Isolated peptides which bind to HLA-B18 molecules and uses thereof

The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-6. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Use of these materials in therapeutic and diagnostic contexts are also a part of the invention.

Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-6 and uses thereof

Growing community of inventors

Brussels, Belgium

Pierre Van Der Bruggen